Skip to main content
. 2019 Jul 10;21(8):1159–1166. doi: 10.1093/europace/euz175

Figure 4.

Figure 4

Relative risks of significant adverse events in trials comparing vernakalant to comparator in patients with recent-onset atrial fibrillation.